# Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly

> **NCT00751751** · PHASE3 · COMPLETED · sponsor: **Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company** · enrollment: 441 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** olmesartan medoxomil + hydrochlorothiazide, if necessary
- **DRUG:** losartan + hydrochlorothiazide, if necessary

## Key facts

- **NCT ID:** NCT00751751
- **Lead sponsor:** Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2005-04
- **Final completion:** 2005-06
- **Target enrollment:** 441 (ACTUAL)
- **Last updated:** 2008-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00751751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00751751, "Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00751751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*